Loading stock data…
CAH
$197.00-0.06 (-0.03%)
Pre-Market$195.00-2.00 (-1.02%)· Last close May 5
Cardinal Health, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cardinal Health, Inc. in the Healthcare sector is trading at $197.00. The stock is currently 16% below its 52-week high of $233.60, remaining 4.3% above its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why CAH maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$197.00
Potential Downside
77.6%
Whystock Fair Value$44.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$247.13+25.4%
Range$215.00 – $275.00
Fundamentals
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company prov...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$47.13B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.86
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.04%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.63%
Volume
Today's trading volume
996,633
Recent News
Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cardinal (CAH) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cardinal (CAH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Jim Cramer on Cardinal: “Gotta Put That One Behind”
Cardinal Health, Inc. (NYSE:CAH) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer mentioned the stock during the episode and said: Cardinal Health, a company that had repeatedly come on Mad Money telling a terrific story, just imploded. Did I tell people to buy it? Well, it’s in […]
CAH Q1 Deep Dive: Specialty Growth, Tariff Dynamics, and Margin Pressures Shape Cardinal Health’s Outlook
Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market’s revenue expectations in Q1 CY2026, but sales rose 11% year on year to $60.94 billion. Its non-GAAP profit of $3.17 per share was 13.7% above analysts’ consensus estimates.
Cardinal Health (CAH) Is Down 5.8% After Mixed Q3 2026 Beat And Higher Earnings Guidance
Cardinal Health, Inc. has reported its third-quarter 2026 results, with sales rising to US$60,940 million while net income declined to US$399 million, and full-year adjusted earnings guidance was raised after beating earnings estimates despite missing revenue expectations. An interesting takeaway is that growth was led by the higher-value Pharmaceutical and Specialty Solutions businesses, even as tariffs and other costs weighed on the GMPD segment’s profit. Next, we’ll examine how Cardinal...